Performance of the monoclonal antibody B72.3 in diagnosis of malignant carcinomatous serous effusions—A systematic review and meta-analysis of diagnostic performance Review
| Authors: | Lin, A. H.; Hsu, M.; Ng, J. K. M.; Farahani, S. J.; Li, J. J. X.; Nano, J.; Raeisi-Dehkordi, H.; Tang, W.; Vielh, P.; Muka, T. |
| Review Title: | Performance of the monoclonal antibody B72.3 in diagnosis of malignant carcinomatous serous effusions—A systematic review and meta-analysis of diagnostic performance |
| Abstract: | Objectives: Immunocytochemistry is often required in the cytologic assessment of malignant serous effusion, particularly for differentiating metastatic carcinoma from mesothelioma. To summarise the diagnostic performance of the monoclonal antibody B72.3, a systematic review and meta-analysis was conducted. Methods: Five databases were searched for relevant studies and reviewed for data extraction and risk of bias assessment. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under curve of summary receiver operating characteristics (AUC-SROC) were calculated for the diagnostic performance of B72.3. Heterogeneity and publication bias were assessed by the I2 index and Deeks' funnel plot. Results: In total, 19 studies (1159 cases) were included. Overall pooled sensitivity and specificity were 0.76 (0.72–0.79) and 0.90 (0.74–1.00), respectively. The NLR, PLR and DOR were 0.27 (0.21–0.34), 7.66 (< 0.001–20.46) and 28.26 (0–75.96), respectively. The AUC-SROC was 0.98, indicating a good overall diagnostic accuracy for B72.3. Subgroup analysis for adenocarcinoma (0.75, 0.71–0.79), mesothelioma (0.92, 0.85–0.98) and benign/reactive mesothelial cells (0.96, 0.93–1.00) showed similar sensitivity and specificity, while the sensitivity for adenocarcinomas of the gastrointestinal/hepatobiliary tract (0.56, 0.41–0.71) and breast (0.55, 0.38–0.71) was significantly lower. High heterogeneity was observed in the majority of our analyses, while no evidence of publication bias was identified. Conclusions: B72.3 has an acceptable performance with low sensitivity. With a good specificity, B72.3 may find use in an immunocytochemical panel for excluding benign mesothelial processes. © 2025 The Author(s). Cytopathology published by John Wiley & Sons Ltd. |
| Keywords: | immunohistochemistry; controlled study; human tissue; area under the curve; follow up; cancer diagnosis; diagnostic accuracy; sensitivity and specificity; adenocarcinoma; quality control; breast; differential diagnosis; odds ratio; pathology; tumor marker; monoclonal antibody; immunology; antibodies, monoclonal; kidney; diagnostic value; immunocytochemistry; systematic review; diagnosis; lung; pleura mesothelioma; mesothelioma; medical literature; salivary gland; serodiagnosis; pleural effusion, malignant; regression analysis; statistical model; meta analysis; receiver operating characteristic; meta-analysis; aspiration cytology; diagnostic test accuracy study; monoclonal antibody b.72.3; metastatic carcinoma; procedures; publication bias; malignant pleura effusion; humans; human; male; female; article; biomarkers, tumor; b72.3; preferred reporting items for systematic reviews and meta-analyses; serous effusion; malignant carcinomatous serous effusion; negative likelihood ratio; positive likelihood ratio |
| Journal Title: | Cytopathology |
| Volume: | 36 |
| Issue: | 4 |
| ISSN: | 0956-5507 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2025-07-01 |
| Start Page: | 399 |
| End Page: | 407 |
| Language: | English |
| DOI: | 10.1111/cyt.13493 |
| PUBMED: | 40207424 |
| PROVIDER: | scopus |
| PMCID: | PMC12150004 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work